<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39224781</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>1401658</StartPage><MedlinePgn>1401658</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1401658</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1401658</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Nirmatrelvir-ritonavir (Paxlovid) has received emergency use authorization from the US Food and Drug Administration owing to its effectiveness and safety. However, data on the effectiveness and safety of Paxlovid use in COVID-19 patients with onset of more than 5 days are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A real-world retrospective study was performed during the outbreak involving the SARS-CoV-2 BA.5.2 subvariant. Hospitalized COVID-19 patients (including mild, moderate, severe and critical cases) were divided into three groups: Paxlovid treatment within (Group A) or more than (Group B) 5 days of COVID-19 onset and no Paxlovid treatment during more than 5 days of COVID-19 onset with only basic symptomatic treatment (Group C). Endpoints were all-cause 28-day mortality, improvement in clinical classification, and a composite endpoint of disease progression, viral load and virus elimination time. Safety was assessed by comparing adverse events reported during treatment in each group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During the period, 248 hospitalized COVID-19 patients, including 55 in Group A, 170 in Group B, and 23 in Group C, were enrolled. There were no significant differences in the clinical classification improvement rate [80.0% (16/20) vs. 81.3% (52/64), <i>p</i> = 1.000; 60.0% (21/35) vs. 55.7% (59/106), <i>p</i> = 0.653, respectively] or all-cause 28-day mortality [0% (0/20) vs. 1.6% (1/64), <i>p</i> = 1.000; 11.4% (4/35) vs. 6.6% (7/106), <i>p</i> = 0.576, respectively] between Groups A and B for nonsevere and severe cases. However, the clinical classification improvement rate in Group B was markedly higher than that in Group C [81.3% (52/64) vs. 50.0% (6/12), <i>p</i> = 0.049] among nonsevere cases. Cycle threshold values of the N and ORF genes in Group B were significantly increased after Paxlovid treatment [31.14 (IQR 26.81-33.93) vs. 38.14 (IQR 36.92-40.00), <i>p</i> &lt; 0.001; 31.33 (IQR 26.00-33.47) vs. 38.62 (IQR 35.62-40.00), <i>p</i> &lt; 0.001, respectively]. No significant differences in reported adverse events of neurological disease (<i>p</i> = 0.571), liver injury (<i>p</i> = 0.960) or kidney injury (<i>p</i> = 0.193) between Group A and Group B were found.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Paxlovid treatment within 10 days of onset can shorten the disease course of COVID-19 by reducing the viral load. Paxlovid is effective and safe in treating COVID-19 with onset of more than five or even 10 days when patients have a high viral load.</AbstractText><CopyrightInformation>Copyright © 2024 Qiu, Wen, Wang, Sun, Li, Li, Wang, Zhai, Zhan, Su, Long, Li and Ye.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Qiu</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology and Respiratory Internal Medicine Department, Guangxi Medical University Cancer Hospital, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wen</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>First Clinical School, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haoru</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangchao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaoqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Jingnan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Yangqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yutian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>First Clinical School, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Zhengtu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ye</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 patients</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">effectiveness and safety</Keyword><Keyword MajorTopicYN="N">onset more than 5 days</Keyword><Keyword MajorTopicYN="N">viral load</Keyword><Keyword MajorTopicYN="N">virus elimination</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39224781</ArticleId><ArticleId IdType="pmc">PMC11366594</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1401658</ArticleId><ArticleId IdType="pii">1401658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Chinese Center for Disease Control and Prevention. National epidemic of novel coronavirus infections. Available at: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.html (Accessed August 7, 2024)
</Citation></Reference><Reference><Citation>Dryden-Peterson S., Kim A., Kim A. Y., Caniglia E. C., Lennes I. T., Patel R., et al. (2023). Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann. Intern Med. 176 (1), 77–84. 10.7326/M22-2141</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2141</ArticleId><ArticleId IdType="pmc">PMC9753458</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., et al. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N. Engl. J. Med. 386 (15), 1397–1408. 10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard J. A., McLaughlin J. M., Malden D., Hong V., Puzniak L., Ackerson B. K., et al. (2023). Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system. medRxiv. 10.1101/2022.10.02.22280623</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.02.22280623</ArticleId><ArticleId IdType="pmc">PMC10081864</ArticleId><ArticleId IdType="pubmed">36933565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Zhang Y., Zhang H., Ai J., He L., Yuan X., et al. (2022). Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in shanghai Omicron wave. Emerg. Microbes Infect. 11 (1), 2045–2054. 10.1080/22221751.2022.2109517</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2109517</ArticleId><ArticleId IdType="pmc">PMC9448390</ArticleId><ArticleId IdType="pubmed">35924388</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., et al. (2023). Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. 76 (3), e342–e349. 10.1093/cid/ciac443</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac443</ArticleId><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Health Commission of the People’s Republic of China. Diagnosis and treatment protocol for novel coronavirus infection (trial version 9). Accessed at: https://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm (Accessed August 7, 2024).
</Citation></Reference><Reference><Citation>Primorac D., Vrdoljak K., Brlek P., Pavelić E., Molnar V., Matišić V., et al. (2022). Adaptive immune responses and immunity to SARS-CoV-2. Front. Immunol. 13, 848582. 10.3389/fimmu.2022.848582</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.848582</ArticleId><ArticleId IdType="pmc">PMC9114812</ArticleId><ArticleId IdType="pubmed">35603211</ArticleId></ArticleIdList></Reference><Reference><Citation>Salguero F. J., White A. D., Slack G. S., Fotheringham S. A., Bewley K. R., Gooch K. E., et al. (2021). Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat. Commun. 12 (1), 1260. 10.1038/s41467-021-21389-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21389-9</ArticleId><ArticleId IdType="pmc">PMC7904795</ArticleId><ArticleId IdType="pubmed">33627662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhao D., Liu X., Chen X., Xiao W., Feng L. (2023). Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J. Med. Virol. 95 (1), e28443. 10.1002/jmv.28443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28443</ArticleId><ArticleId IdType="pmc">PMC9880690</ArticleId><ArticleId IdType="pubmed">36579782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C. K. H., Au I. C. H., Lau K. T. K., Lau E. H. Y., Cowling B. J., Leung G. M. (2022a). Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. 22 (12), 1681–1693. 10.1016/S1473-3099(22)00507-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00507-2</ArticleId><ArticleId IdType="pmc">PMC9401976</ArticleId><ArticleId IdType="pubmed">36029795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C. K. H., Au I. C. H., Lau K. T. K., Lau E. H. Y., Cowling B. J., Leung G. M. (2022b). Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 400 (10359), 1213–1222. 10.1016/S0140-6736(22)01586-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01586-0</ArticleId><ArticleId IdType="pmc">PMC9539539</ArticleId><ArticleId IdType="pubmed">36216007</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int (Accessed November 28, 2023).
</Citation></Reference><Reference><Citation>Yang M. J., Jiang L., Xu L., Guo S. L. (2023). Association between Paxlovid and mortality rates in critically ill patients with COVID-19 receiving invasive mechanical ventilation: a retrospective cohort study. Chest 19 (1), 128–131. 10.1016/j.chest.2023.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.07.012</ArticleId><ArticleId IdType="pubmed">37473858</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip T. C., Lui G. C., Lai M. S., Wong V. W., Tse Y. K., Ma B. H., et al. (2023). Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin. Infect. Dis. 76 (3), e26–e33. 10.1093/cid/ciac687</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac687</ArticleId><ArticleId IdType="pmc">PMC9452147</ArticleId><ArticleId IdType="pubmed">36031408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>